Questioning the Bacterial Overgrowth Hypothesis of Irritable Bowel Syndrome: An Epidemiologic and Evolutionary Perspective

被引:44
作者
Spiegel, Brennan M. R. [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA
[6] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA 90095 USA
关键词
Irritable Bowel Syndrome; Small Intestinal Bacterial Overgrowth; Epidemiology; PLACEBO-CONTROLLED TRIAL; FUNCTIONAL GASTROINTESTINAL DISORDERS; CHLORIDE CHANNEL ACTIVATOR; GULF-WAR VETERANS; DOUBLE-BLIND; BREATH TEST; CHRONIC CONSTIPATION; RECEPTOR ANTAGONIST; HEALTHY CONTROLS; CLINICAL-TRIAL;
D O I
10.1016/j.cgh.2011.02.030
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Although studies indicate that small intestinal bacterial overgrowth (SIBO) is prevalent in irritable bowel syndrome (IBS), it remains unclear whether SIBO causes IBS. This review presents an epidemiologic and evolutionary inquiry that questions the bacterial overgrowth hypothesis of IBS, as follows. (1) Although the hypothesis may be biologically plausible, there is also a strong rationale for competing hypotheses; it is unlikely that SIBO is the predominant cause of IBS in all comers, because competing explanations are sensible and defensible. Moreover, data indicate that the test used to promulgate the SIBO hypothesis - the lactulose hydrogen breath test - may not have measured SIBO in the first place. (2) We do not have evidence of SIBO being absent before IBS symptoms, and present after IBS emerges. (3) There is not a dose-response relationship between small intestinal microbiota and IBS symptoms. (4) The relationship between SIBO and IBS is highly inconsistent among studies. (5) Many effective IBS therapies do not address SIBO at all, yet have a more favorable "number needed to treat" than antibiotics. (6) IBS does not behave like a traditional infectious disease, suggesting that microbes may not principally cause the syndrome. (7) Other factors may confound the relationship between SIBO and IBS, including proton pump inhibitors. (8) Whereas the brain-gut hypothesis is evolutionary sensible, the bacterial hypothesis is harder to defend from an evolutionary perspective. The article concludes that bacteria may contribute to some IBS symptoms, but that bacteria cannot be the only explanation, and a causal link between SIBO and IBS is not secure.
引用
收藏
页码:461 / 469
页数:9
相关论文
共 96 条
  • [1] ABRAHAM R, 2007, GASTROENTEROLOGY S1, V132, pS1068
  • [2] Bardhan KD, 2000, ALIMENT PHARM THERAP, V14, P23
  • [3] Association Between Intimate Partner Violence and Irritable Bowel Syndrome: A Population-Based Study in Nicaragua
    Becker-Dreps, Sylvia
    Morgan, Douglas
    Pena, Rodolfo
    Cortes, Loreto
    Martin, Christopher F.
    Valladares, Eliette
    [J]. VIOLENCE AGAINST WOMEN, 2010, 16 (07) : 832 - 845
  • [4] An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
    Brandt, Lawrence J.
    Chey, William D.
    Foxx-Orenstein, Amy E.
    Quigley, Eamonn M. M.
    Schiller, Lawrence R.
    Schoenfeld, Philip S.
    Spiegel, Brennan M.
    Talley, Nicholas J.
    Moayyedi, Paul
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S1 - S36
  • [5] Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls
    Bratten, Jason R.
    Spanier, Jennifer
    Jones, Michael P.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (04) : 958 - 963
  • [6] Differential Expression of Toll-Like Receptors in Patients With Irritable Bowel Syndrome
    Brint, Elizabeth K.
    MacSharry, John
    Fanning, Aine
    Shanahan, Fergus
    Quigley, Eamonn M. M.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (02) : 329 - 336
  • [7] A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome
    Camilleri, M
    Chey, WY
    Mayer, EA
    Northcutt, AR
    Heath, A
    Dukes, GE
    McSorley, D
    Mangel, AM
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (14) : 1733 - 1740
  • [8] Camilleri M, 1999, ALIMENT PHARM THERAP, V13, P1149
  • [9] Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome
    Camilleri, Michael
    Mckinzie, Sanna
    Busciglio, Irene
    Low, Phillip A.
    Sweetser, Seth
    Burtow, Duane
    Baxter, Kari
    Ryks, Michael
    Zinsmeister, Alan R.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (07) : 772 - 781
  • [10] Chou JY, 2010, GASTROENTEROLOGY, V138, pS229